Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;13(55):3246-3249.
doi: 10.1016/j.med.2022.05.005. Epub 2022 May 12.

[Treatment protocol for COVID-19 in patients with and without an indication for hospital admission]

[Article in Spanish]
G Hernández García  1 , J M Barbero Allende  1 , F García Sánchez Y J Sanz Moreno  1
Affiliations

[Treatment protocol for COVID-19 in patients with and without an indication for hospital admission]

[Article in Spanish]
G Hernández García et al. Medicine (Madr). 2022 May.

Abstract
in English, Spanish

SARS-CoV-2 infection causes a wide spectrum of symptoms with varying degrees of severity, from asymptomatic cases or cases in the form of self-limiting influenza-like illness to cases of rapidly progressing respiratory distress syndrome due to an anomalous immune system response in the form of a cytokine storm. Thrombotic complications are also common. Multiple antiviral treatments have been tested in COVID-19 without favorable outcomes. Only remdesivir may be useful, but not in all cases, and its use is controversial. On the contrary, immunomodulating treatments have the most solid evidence, particularly glucocorticoids. Other more specific immunosuppressors, such as interleukin-6 inhibitors, have also shown favorable results and many others are currently being studied. Thromboprophylaxis is the other pillar of COVID-19 treatment, although the anticoagulant dose to be used is still being discussed.

La infeccion por SARS-CoV-2 causa un amplio espectro de sintomas con distintos grados de severidad; desde casos asintomaticos o en forma de sindrome pseudogripal autolimitado, hasta un sindrome de distres respiratorio rapidamente progresivo debido a una respuesta anomala del sistema inmunitario en forma de tormenta de citoquinas. Tambien son frecuentes las complicaciones tromboticas. Multiples tratamientos antivirales se han probado en la COVID-19 sin resultados favorables, tan solo remdesivir puede ser util, pero no en todos los casos, y su uso es controvertido. Por el contrario, son los tratamientos inmunomoduladores los que mas solida evidencia de beneficio han acumulado, particularmente los corticoides. Otros inmunosupresores mas especificos, como los inhibidores de la interleuquina 6, tambien han logrado resultados favorables, y muchos otros estan actualmente en estudio. La tromboprofilaxis es el otro pilar del tratamiento de la COVID-19, aunque la dosis anticoagulante a emplear todavia esta en discusion.

Keywords: Glucocorticoids; Low-molecular-weight heparin; Remdesivir; Tocilizumab.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Protocolo de tratamiento de la COVID-19 en pacientes con y sin indicación de ingreso hospitalario. HBPM: heparina de bajo peso molecular.
See this image and copyright information in PMC

References

    1. fx5 Yu L.M., Bafadhel M., Dorward J., Hayward G., Saville B.R., Gbinigie O., et al. PRINCIPLE Trial Collaborative Group. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;398(10303):843–855. - PMC - PubMed
    1. fx5 fx2 Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, et al., BLAZE-1 Investigators. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021:NEJMoa2102685. - PMC - PubMed
    1. fx5 fx2 ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators, Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, et al. Therapeutic anticoagulation with heparin in noncritically Ill patients with Covid-19. N Engl J Med. 2021; 385(9):790-802. - PMC - PubMed
    1. fx5 fx2 RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021; 384(8):693-704. - PMC - PubMed
    1. fx5 fx2 Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., et al. ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813–1826. - PMC - PubMed

Publication types

LinkOut - more resources